Advertisement

Pediatric Cardiology

, Volume 40, Issue 3, pp 650–657 | Cite as

Practice Variation, Costs and Outcomes Associated with the Use of Inhaled Nitric Oxide in Pediatric Heart Transplant Recipients

  • David W. BearlEmail author
  • Debra A. Dodd
  • Cary Thurm
  • Matt Hall
  • Jonathan H. Soslow
  • Brian Feingold
  • Justin Godown
Original Article
  • 83 Downloads

Abstract

Right ventricular (RV) failure is a potentially fatal complication following heart transplantation (HTx). Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that is used to decrease pulmonary vascular resistance immediately post-HTx to reduce the risk of RV failure. The aim of this study was to describe utilization patterns, costs, and outcomes associated with post-transplant iNO use in children. All pediatric HTx recipients (2002–2016) were identified from a unique linked PHIS/SRTR dataset. Post-HTx iNO use was determined based on hospital billing data. Utilization patterns and associated costs were described. The association of iNO support with post-HTx survival was assessed using the Kaplan–Meier method and a multivariable Cox proportional hazards model was used to adjust for risk factors. A total of 2833 pediatric HTx recipients from 28 centers were identified with 1057 (36.5%) receiving iNO post-HTx. Post-HTx iNO use showed significant increase overall (17.2–54.7%, p < 0.001) and wide variation among centers (9–100%, p < 0.001). Patients with congenital heart disease (aOR 1.4, 95% CI 1.2, 1.6), requiring mechanical ventilation at HTx (aOR 1.3, 95% CI 1.1, 1.6), and pre-transplant iNO (aOR 9.3, 95% CI 5.4, 16) were more likely to receive iNO post-HTx. The median daily cost of iNO was $2617 (IQR $1843–$3646). Patients who required > 5 days of iNO post-HTx demonstrated inferior 1-year post-HTx survival (p < 0.001) and iNO use > 5 days was independently associated with worse post-HTx survival (AHR 1.6, 95% CI 1.2, 2.1; p < 0.001). There is wide variation in iNO use among centers following pediatric HTx with use increasing over time despite significant incremental cost. Prolonged iNO use post-HTx is associated with worse survival, likely serving as a marker of residual illness severity. Further research is needed to define the populations that derive the greatest benefit from this costly therapy.

Keywords

Child Heart transplantation Nitric oxide Heart failure Vasodilator agents 

Notes

Funding

This project was supported through internal funding from the Katherine Dodd Faculty Scholar Program at Vanderbilt University (JG). Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K23HL123938 (Bethesda, MD) (JS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Disclosures

The data reported here have been supplied by the Minneapolis Medical Research Foundation as the contractor for the SRTR. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the U.S. Government.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informal Consent

For this type of study formal consent is not required.

References

  1. 1.
    Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M et al (2014) Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart Lung Transplant 33(4):327–340.  https://doi.org/10.1016/j.healun.2014.02.027 CrossRefPubMedGoogle Scholar
  2. 2.
    Huang J, Trinkaus K, Huddleston CB, Mendeloff EN, Spray TL, Canter CE (2004) Risk factors for primary graft failure after pediatric cardiac transplantation: importance of recipient and donor characteristics. J Heart Lung Transplant 23(6):716–722.  https://doi.org/10.1016/j.healun.2003.08.001 CrossRefPubMedGoogle Scholar
  3. 3.
    Hoskote A, Carter C, Rees P, Elliott M, Burch M, Brown K (2010) Acute right ventricular failure after pediatric cardiac transplant: predictors and long-term outcome in current era of transplantation medicine. J Thorac Cardiovasc Surg 139(1):146–153.  https://doi.org/10.1016/j.jtcvs.2009.08.020 CrossRefPubMedGoogle Scholar
  4. 4.
    Davies RR, Russo MJ, Mital S, Martens TM, Sorabella RS, Hong KN, Gelijns AC, Moskowitz AJ, Quaegebeur JM, Mosca RS, Chen JM (2008) Predicting survival among high-risk pediatric cardiac transplant recipients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 135(1):147–155, 155 e141–142.  https://doi.org/10.1016/j.jtcvs.2007.09.019.
  5. 5.
    Checchia PA, Bronicki RA, Goldstein B (2012) Review of inhaled nitric oxide in the pediatric cardiac surgery setting. Pediatr Cardiol 33(4):493–505.  https://doi.org/10.1007/s00246-012-0172-4 CrossRefPubMedGoogle Scholar
  6. 6.
    Sabato LA, Salerno DM, Moretz JD, Jennings DL (2017) Inhaled pulmonary vasodilator therapy for management of right ventricular dysfunction after left ventricular assist device placement and cardiac transplantation. Pharmacotherapy 37(8):944–955.  https://doi.org/10.1002/phar.1959 CrossRefPubMedGoogle Scholar
  7. 7.
    Benedetto M, Romano R, Baca G, Sarridou D, Fischer A, Simon A, Marczin N (2015) Inhaled nitric oxide in cardiac surgery: evidence or tradition? Nitric Oxide 49:67–79.  https://doi.org/10.1016/j.niox.2015.06.002 CrossRefPubMedGoogle Scholar
  8. 8.
    Ofori-Amanfo G, Hsu D, Lamour JM, Mital S, O’Byrne ML, Smerling AJ, Chen JM, Mosca R, Addonizio LJ (2011) Heart transplantation in children with markedly elevated pulmonary vascular resistance: impact of right ventricular failure on outcome. J Heart Lung Transplant 30(6):659–666.  https://doi.org/10.1016/j.healun.2010.12.007 CrossRefPubMedGoogle Scholar
  9. 9.
    Daftari B, Alejos JC, Perens G (2010) Initial experience with sildenafil, bosentan, and nitric oxide for pediatric cardiomyopathy patients with elevated pulmonary vascular resistance before and after orthotopic heart transplantation. J Transplant 2010:656984.  https://doi.org/10.1155/2010/656984 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK et al (2015) Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 132(21):2037–2099.  https://doi.org/10.1161/CIR.0000000000000329 CrossRefPubMedGoogle Scholar
  11. 11.
    McGinn K, Reichert M (2016) A comparison of inhaled nitric oxide versus inhaled epoprostenol for acute pulmonary hypertension following cardiac surgery. Ann Pharmacother 50(1):22–26.  https://doi.org/10.1177/1060028015608865 CrossRefPubMedGoogle Scholar
  12. 12.
    Godown J, Thurm C, Dodd DA, Soslow JH, Feingold B, Smith AH, Mettler BA, Thompson B, Hall M (2017) A unique linkage of administrative and clinical registry databases to expand analytic possibilities in pediatric heart transplantation research. Am Heart J 194:9–15.  https://doi.org/10.1016/j.ahj.2017.08.014 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bhatia SJ, Kirshenbaum JM, Shemin RJ, Cohn LH, Collins JJ, Di Sesa VJ, Young PJ, Mudge GH Jr, Sutton MG (1987) Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation 76(4):819–826CrossRefPubMedGoogle Scholar
  14. 14.
    George I, Xydas S, Topkara VK, Ferdinando C, Barnwell EC, Gableman L, Sladen RN, Naka Y, Oz MC (2006) Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg 82(6):2161–2169.  https://doi.org/10.1016/j.athoracsur.2006.06.081 CrossRefPubMedGoogle Scholar
  15. 15.
    Fukushima N, Gundry SR, Razzouk AJ, Bailey LL (1994) Risk factors for graft failure associated with pulmonary hypertension after pediatric heart transplantation. J Thorac Cardiovasc Surg 107(4):985–989.  https://doi.org/10.1016/S0022-5223(94)70273-8 PubMedGoogle Scholar
  16. 16.
    Chiu P, Russo MJ, Davies RR, Addonizio LJ, Richmond ME, Chen JM (2012) What is high risk? Redefining elevated pulmonary vascular resistance index in pediatric heart transplantation. J Heart Lung Transplant 31(1):61–66.  https://doi.org/10.1016/j.healun.2011.08.021 CrossRefPubMedGoogle Scholar
  17. 17.
    Buddhe S, Du W, L’Ecuyer T (2012) Impact of pulmonary hypertension on transplant outcomes in pediatric cardiomyopathy patients. Pediatr Transplant 16(4):367–372.  https://doi.org/10.1111/j.1399-3046.2012.01678.x CrossRefPubMedGoogle Scholar
  18. 18.
    Paniagua MJ, Crespo-Leiro MG, Rodriguez JA, Fojon S, Pastor J, Castro MJ, Hermida LF, Cuenca JJ, Juffe-Stein A, Castro-Beiras A (1999) Usefulness of nitric oxide inhalation for management of right ventricular failure after heart transplantation in patients with pretransplant pulmonary hypertension. Transplant Proc 31(6):2505–2506CrossRefPubMedGoogle Scholar
  19. 19.
    Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D, Moriguchi J, Hamilton MA, Kobashigawa J, Laks H (2001) Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 72(4):638–641CrossRefPubMedGoogle Scholar
  20. 20.
    Richmond ME, Law YM, Das BB, Everitt MD, Kukreja M, Naftel DC et al (2015) Elevated pre-transplant pulmonary vascular resistance is not associated with mortality in children without congenital heart disease: a multicenter study. J Heart Lung Transplant 34(3):448–456.  https://doi.org/10.1016/j.healun.2014.04.021 CrossRefPubMedGoogle Scholar
  21. 21.
    Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ et al (2017) The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 36(10):1037–1046.  https://doi.org/10.1016/j.healun.2017.07.019 CrossRefPubMedGoogle Scholar
  22. 22.
    Villa CR, Khan MS, Zafar F, Morales DLS, Lorts A (2017) United States trends in pediatric ventricular assist implantation as bridge to transplantation. ASAIO J 63(4):470–475.  https://doi.org/10.1097/MAT.0000000000000524 CrossRefPubMedGoogle Scholar
  23. 23.
    Tsukashita M, Takayama H, Takeda K, Han J, Colombo PC, Yuzefpolskaya M, Topkara VK, Garan AR, Mancini DM, Kurlansky PA, Naka Y (2015) Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival. J Thorac Cardiovasc Surg 150(5):1352–1360, 1361 e1351–1352.  https://doi.org/10.1016/j.jtcvs.2015.07.012
  24. 24.
    Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR, Borlaug BA (2017) Hemodynamics of Fontan failure: the role of pulmonary vascular disease. Circ Heart Fail.  https://doi.org/10.1161/CIRCHEARTFAILURE.117.004515 PubMedPubMedCentralGoogle Scholar
  25. 25.
    Mitchell MB, Campbell DN, Ivy D, Boucek MM, Sondheimer HM, Pietra B, Das BB, Coll JR (2004) Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg 128(5):693–702.  https://doi.org/10.1016/j.jtcvs.2004.07.013 CrossRefPubMedGoogle Scholar
  26. 26.
    Germann P, Braschi A, Della Rocca G, Dinh-Xuan AT, Falke K, Frostell C et al (2005) Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med 31(8):1029–1041.  https://doi.org/10.1007/s00134-005-2675-4 CrossRefPubMedGoogle Scholar
  27. 27.
    Godown J, Thurm C, Hall M, Soslow JH, Feingold B, Mettler BA, Smith AH, Bearl DW, Dodd DA (2018) Changes in pediatric heart transplant hospitalization costs over time. Transplantation.  https://doi.org/10.1097/TP.0000000000002202 PubMedGoogle Scholar
  28. 28.
    Lorch SA, Cnaan A, Barnhart K (2004) Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics 114(2):417–426CrossRefPubMedGoogle Scholar
  29. 29.
    Brown AT, Gillespie JV, Miquel-Verges F, Holmes K, Ravekes W, Spevak P et al (2012) Inhaled epoprostenol therapy for pulmonary hypertension: improves oxygenation index more consistently in neonates than in older children. Pulm Circ 2(1):61–66.  https://doi.org/10.4103/2045-8932.94835 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH (2002) Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. The J Pediatr 141(6):830–832.  https://doi.org/10.1067/mpd.2002.129849 CrossRefPubMedGoogle Scholar
  31. 31.
    De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, Zanaboni PB, Moazami N, Smith JR (2004) Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 127(4):1058–1067.  https://doi.org/10.1016/j.jtcvs.2003.11.035 CrossRefPubMedGoogle Scholar
  32. 32.
    Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M (2001) Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 103(4):544–548CrossRefPubMedGoogle Scholar
  33. 33.
    Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P (2008) Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 129(3):333–338.  https://doi.org/10.1016/j.ijcard.2007.08.084 CrossRefPubMedGoogle Scholar
  34. 34.
    Theodoraki K, Tsiapras D, Tsourelis L, Zarkalis D, Sfirakis P, Kapetanakis E, Alivizatos P, Antoniou T (2006) Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand 50(10):1213–1217.  https://doi.org/10.1111/j.1399-6576.2006.01139.x CrossRefPubMedGoogle Scholar
  35. 35.
    Haraldsson A, Kieler-Jensen N, Ricksten SE (1996) Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 10(7):864–868CrossRefPubMedGoogle Scholar
  36. 36.
    Khan TA, Schnickel G, Ross D, Bastani S, Laks H, Esmailian F, Marelli D, Beygui R, Shemin R, Watson L, Vartapetian I, Ardehali A (2009) A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg 138(6):1417–1424.  https://doi.org/10.1016/j.jtcvs.2009.04.063 CrossRefPubMedGoogle Scholar
  37. 37.
    Theodoraki K, Thanopoulos A, Rellia P, Leontiadis E, Zarkalis D, Perreas K, Antoniou T (2017) A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension. Heart Vessels 32(12):1488–1497.  https://doi.org/10.1007/s00380-017-1023-2 CrossRefPubMedGoogle Scholar
  38. 38.
    Lamarche Y, Perrault LP, Maltais S, Tetreault K, Lambert J, Denault AY (2007) Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg 31(6):1081–1087.  https://doi.org/10.1016/j.ejcts.2007.02.019 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatric Cardiology, Monroe Carell Jr. Children’s HospitalVanderbilt UniversityNashvilleUSA
  2. 2.Children’s Hospital AssociationLenexaUSA
  3. 3.Pediatrics and Clinical and Translational ResearchUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations